Moderna FY2028 EPS Cut by Brookline Capital Markets

Moderna, Inc. (NASDAQ:MRNA) – Equities researchers at Brookline Capital Markets lowered their FY2028 earnings per share estimates for Moderna in a research report issued on Friday, July 31st. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn $0.53 per share for the year, down from their previous forecast of $0.68. The consensus estimate for Moderna’s current full-year earnings is ($6.05) per share. Brookline Capital Markets also issued estimates for Moderna’s FY2029 earnings at $11.69 EPS and FY2030 earnings at $19.27 EPS.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same quarter in the previous year, the company earned ($2.13) EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year.

Other analysts have also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Moderna in a research note on Friday, June 12th. UBS Group reiterated an “overweight” rating on shares of Moderna in a research note on Monday. The Goldman Sachs Group boosted their target price on Moderna from $49.00 to $67.00 and gave the stock a “neutral” rating in a report on Tuesday, July 21st. Jefferies Financial Group restated a “hold” rating on shares of Moderna in a research report on Thursday, June 18th. Finally, Wolfe Research reiterated an “underperform” rating and issued a $25.00 price objective on shares of Moderna in a research report on Monday, July 20th. Three investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and five have issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $42.13.

Moderna Trading Up 3.5%

Shares of Moderna stock opened at $57.08 on Monday. Moderna has a 12-month low of $22.28 and a 12-month high of $85.60. The stock has a market capitalization of $22.79 billion, a P/E ratio of -7.14 and a beta of 0.91. The company has a 50-day simple moving average of $59.74 and a 200 day simple moving average of $52.87. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09.

Institutional Investors Weigh In On Moderna

Several institutional investors have recently modified their holdings of the business. Allied Private Wealth LLC bought a new position in Moderna in the second quarter valued at approximately $30,000. Canton Hathaway LLC acquired a new stake in shares of Moderna during the first quarter worth $31,000. Assetmark Inc. increased its holdings in Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock valued at $41,000 after purchasing an additional 208 shares during the last quarter. Strategic Investment Solutions Inc. IL acquired a new position in Moderna in the second quarter valued at about $61,000. Finally, MUFG Securities EMEA plc bought a new position in Moderna during the second quarter worth about $28,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Buying and Selling

In other news, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the sale, the insider owned 67,468 shares in the company, valued at $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Noubar Afeyan sold 9,263 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $46.84, for a total value of $433,878.92. Following the completion of the transaction, the director owned 3,924 shares in the company, valued at approximately $183,800.16. This represents a 70.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 119,406 shares of company stock worth $5,928,762 in the last quarter. Insiders own 10.80% of the company’s stock.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna administered the first doses in a Phase 1 trial of mRNA-1469, an investigational vaccine targeting Bundibugyo ebolavirus. The strain has no licensed vaccine, and the study will assess safety and immune response in Canada following Health Canada authorization. The program, developed with support from the Coalition for Epidemic Preparedness Innovations, highlights the potential speed and flexibility of Moderna’s mRNA platform. Moderna begins first human trial of Bundibugyo Ebola vaccine
• Positive Sentiment: Investors viewed the Ebola program as a potential long-term opportunity, particularly because a deadly outbreak has increased demand for protection against the virus and there is currently no approved vaccine for this strain. However, the candidate is only entering Phase 1, so any commercial benefit remains uncertain and several years away. Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine
• Neutral Sentiment: Brookline Capital Markets modestly improved its 2026 quarterly and full-year loss estimates, forecasting a $6.60 per-share loss for 2026 versus its prior $7.26 estimate. The firm still expects losses in 2027, though its forecast deteriorated sharply to a $3.24 per-share loss from a previous $0.08 loss, signaling limited near-term profitability visibility.
• Negative Sentiment: Moderna’s Phase 3 norovirus vaccine trial showed no early success, raising concerns about another potential setback in the company’s pipeline and increasing reliance on its respiratory vaccine franchise and earlier-stage programs. No early success for Moderna’s norovirus vaccine in phase 3 trial

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.